Post-authorisation safety study (PASS): observational cohort study of PAH patients newly treated with either UPTRAVI (selexipag) or any other PAH-specific therapy, in clinical practice (EXPOSURE) First published 12/05/2017 Last updated 15/04/2026 EU PAS number:EUPAS19085 Study Ongoing